MAP2K7 and head and neck squamous cell carcinoma: Afatinib, an irreversible inhibitor of EGFR, HER2, and HER4, was studied in combination with the MEK inhibitor PD0325901, with the aim to inhibit cisplatin-resistant HNSCC cells lines.